Palliser Capital Challenges Recordati Board on €53 Offer Clarity…

Event summary

Palliser Capital demands Recordati’s independent directors clarify their stance on the revised €53.00 per share CVC-led offer by October 16, 2026.
Recordati’s board statement on October 7, 2026, was interpreted as an endorsement, but Palliser argues it lacks a fairness opinion or recommendation.
The offer price is €1 above the lower end of Rothschild’s DCF range and below Bloomberg’s consensus target of €60.10.
Palliser, a Recordati shareholder, refuses to tender its shares, citing the offer’s inadequacy and coercive structure.

The big picture

Palliser’s challenge highlights the tension between activist shareholders and board governance in European takeovers. The dispute over Recordati’s valuation—amid strong growth in its Rare Diseases business—could influence how similar deals are structured in Italy’s pharmaceutical sector. The outcome will test the balance of power between independent directors and private equity bidders.

What we're watching

Governance Dynamics: Whether Recordati’s independent directors will publicly clarify their position, setting a precedent for minority shareholder rights in Italy.
Valuation Discrepancy: How the market will react if the offer is deemed inadequate, especially given Recordati’s 22% growth in its Rare Diseases segment.
Activist Pressure: The likelihood of other shareholders joining Palliser in opposing the offer, potentially derailing the CVC-led acquisition.